Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Meta-Analysis

Dhaval Kolte1,2, Suvasini Lakshmanan1, Matthew D Jankowich1,2,3

  • 11 Providence Veterans Affairs Medical Center Warren Alpert Medical School of Brown University Providence RI.

Insights

Mild pulmonary hypertension (PH), defined as mean pulmonary artery pressure >19 mm Hg, is linked to a significantly increased mortality risk. This finding supports earlier diagnosis and intervention for patients with mild PH to improve outcomes.

Area of Science:

  • Cardiology
  • Pulmonology
  • Clinical Risk Assessment

Background:

  • Recent studies suggest a clinical risk continuum for pulmonary artery pressure (PAP) starting above 19 mm Hg, below the traditional 25 mm Hg threshold for pulmonary hypertension (PH).
  • The generalizability and validity of this lower threshold require confirmation due to its implications for patient diagnosis and prognosis.

Purpose of the Study:

  • To confirm the association between mildly elevated mean PAP and all-cause mortality.
  • To evaluate the risk of mortality in patients with mild PH compared to a referent group.

Main Methods:

  • A meta-analysis of 15 nonrandomized studies including 16,482 patients (7451 with mild PH: 19-24 mm Hg) was conducted.
  • Data were sourced from databases up to January 31, 2018, utilizing right heart catheterization and echocardiography measurements.
  • Follow-up duration averaged 5.2 years.

Main Results:

  • Mild PH was associated with a 52% increased risk of mortality (Risk Ratio: 1.52; 95% CI: 1.32-1.74).
  • Risk-adjusted time-to-event analysis showed a similar increase (Hazard Ratio: 1.19; 95% CI: 1.09-1.31).
  • Findings were consistent across measurement methods, and publication bias did not significantly alter the risk estimate.

Conclusions:

  • An elevated risk of mortality exists in patients with mild PH (mean PAP >19 mm Hg).
  • These findings highlight the need for diagnosing and considering mild PH patients for clinical studies on interventions to mitigate risk and enhance outcomes.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
645
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
619
Review and Preview01:10

Review and Preview

In statistics, several tools are used to interpret the data. Measures of central tendency represent the characteristics of the data, such as mean, median, and mode. Additionally, measures of variance like standard deviation and range are used to find the spread of data from the mean. Relative standing measures the distance between data locations. Commonly used measures of relative standings are percentile, z score, and quartiles.
Percentiles are a type of fractile that partition data into...
8.4K